trending Market Intelligence /marketintelligence/en/news-insights/trending/eiFnpfX8uc8V_006TlGfGw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Bayer enters licensing deal for US rights to Daré contraceptive Ovaprene

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Bayer enters licensing deal for US rights to Daré contraceptive Ovaprene

Bayer AG agreed to acquire a license that grants the company an option to commercialize Daré Bioscience Inc.'s experimental contraceptive product Ovaprene in the U.S. after the intervaginal ring is approved.

San Diego-based Daré Bioscience will have full control of the development and regulatory processes access, while Bayer will allow the company access to its clinical and market resources.

Under the agreement, Daré will receive an up-front payment of $1 million and access to Bayer's clinical and market capabilities while retaining control over Ovaprene’s development and regulatory approval process.

If Bayer makes a payment of $20 million to Daré, which plans to apply for reimbursement of clinical study costs, then the exclusive license to commercialize Ovaprene in the U.S. will become effective.

According to a Jan. 13 press release, Daré will also be eligible to receive up to $310 million in potential milestone payments as well as double-digit tiered royalties on net sales.

Daré expects to apply in the first half of 2020 to start clinical studies for the device in the U.S. and plans to begin trials in the second half, subject to the U.S. Food and Drug Administration's approval.

Results from the clinical trials are expected to support marketing applications in the U.S., Europe and elsewhere.